Bie Bihua, Wu Jiang, Foss Joseph F, Naguib Mohamed
Department of General Anesthesia, Anesthesiology Institute, Cleveland Clinic, and Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Curr Opin Anaesthesiol. 2018 Aug;31(4):407-414. doi: 10.1097/ACO.0000000000000616.
This narrative review summarizes recent insights into the role of the cannabinoid type 2 (CB2) receptor as potential therapeutic target in neuropathic pain and neurodegenerative conditions.
The cannabinoid system continues to receive attention as a therapeutic target. The CB2 receptor is primarily expressed on glial cells only when there is active inflammation and appears to be devoid of undesired psychotropic effects or addiction liability. The CB2 receptor has been shown to have potential as a therapeutic target in models of diseases with limited or no currently approved therapies, such as neuropathic pain and neurodegenerative conditions such as Alzheimer's disease.
The functional involvement of CB2 receptor in neuropathic pain and other neuroinflammatory diseases highlights the potential therapeutic role of drugs acting at the CB2 receptor.
本叙述性综述总结了近期对2型大麻素（CB2）受体作为神经性疼痛和神经退行性疾病潜在治疗靶点作用的见解。
大麻素系统作为治疗靶点持续受到关注。CB2受体仅在有活动性炎症时主要在胶质细胞上表达，似乎没有不良精神作用或成瘾倾向。在目前批准治疗方法有限或没有的疾病模型中，如神经性疼痛和神经退行性疾病如阿尔茨海默病，CB2受体已显示出作为治疗靶点的潜力。
CB2受体在神经性疼痛和其他神经炎症性疾病中的功能参与突出了作用于CB2受体的药物的潜在治疗作用。
